Latest Regulatory Developments News

FleetPartners has received a non-binding, conditional indicative offer from SG Fleet to acquire all outstanding shares at A$3.601 each, subject to due diligence and regulatory approvals.

Strike Resources is progressing the sale of a 28.52% indirect stake in its high-grade Apurímac Iron Ore Project for A$5.5 million, while advancing exploration programs and preparing for potential small-scale mining under Peru’s artisanal regime. The company also holds a 27.7% interest in LE Minerals, which is spinning out its Graphite Projects via an IPO.

Northern Minerals propels its Browns Range Heavy Rare Earths Project forward with a planned Final Investment Decision in Q3 2026 and a significant 40% increase in the Dazzler Deposit resource.

Sprintex boosted its commercial footprint in the June quarter with a 65% order book increase from Mest Water, a paid trial at Taiwan's TSMC, and Dutch regulatory clearance lifting key uncertainties.

KALiNA Power has strengthened its foothold in Alberta’s booming AI data centre sector, securing a C$18 million load sale to Meta alongside key regulatory reforms that enhance project flexibility and commercial prospects.

Whitehaven Coal delivered a robust finish to FY26, hitting top-end guidance for production and sales while improving safety and reducing costs.

Frasers Group has extended the deadline for its on-market takeover bid for Accent Group shares to 30 September 2026, maintaining all other offer terms unchanged.

ECS Botanics delivered a fourth consecutive quarter of positive operating cash flow in Q4 FY26, with a full-year turnaround of $5.9 million. The company’s branded B2C revenue surged 31% year-on-year, supported by product launches and European market expansion.

The Federal Treasurer has barred three foreign shareholders from exercising voting rights in Northern Minerals due to non-compliance with mandated share divestments, intensifying regulatory oversight amid ongoing FIRB investigations.

Rural Funds Group has exchanged contracts to sell five agricultural assets for $255.6 million, trimming gearing to a pro forma 31.6% and reaffirming its FY26 income forecast.

Qoria Limited marked a turning point in FY25, delivering 25% growth in Annual Recurring Revenue and a 684% jump in underlying EBITDA, setting sights on 20% EBITDA margin in FY26 amid global digital safety expansion.

Island Pharmaceuticals is progressing its broad-spectrum antiviral Galidesivir amid a severe Ebola outbreak, securing government approvals in Uganda and outlining a dual clinical and regulatory development pathway targeting multiple deadly filoviruses.